Bryleos
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bryleos - overview
Established
2021
Location
-, TN, US
Primary Industry
Biotechnology
About
Based in Tennessee, US, and founded in 2021 by CEO Wendy Komac and CFO Filip Pinter, BioNADrx Holdings, Inc. doing business as Bryleos operates as a neuroscience-based company developing treatment for neurological disorders. In June 2023, Bryleos raised USD 5 million in seed funding. Bryleos provides an oral composition of NAD+ for patients suffering from chronic diseases in the healthcare sector.
The company’s technology NAD is a pivotal molecule governing crucial aspects such as enzyme activity, DNA repair, oxidative stress, and inflammation. The firm also focuses on improving intracellular NAD levels in the client's body. Bryleos provides the ability to identify and alleviate withdrawal symptoms caused by alcohol, short-acting opiates, benzodiazepines, methamphetamines, and any combination of these substances. The company also offers treatment for neuropsychology, neurodegenerative disease, and neuronal health and function.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.bryleos.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.